Coronary artery bypass – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:13:48 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Coronary artery bypass – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Levosimendan Before Tricuspid Valve Surgery in Patients with Right Ventricular Dysfunction https://clinicaltrials.eu/trial/study-of-levosimendan-vs-placebo-for-patients-with-right-ventricular-dysfunction-undergoing-tricuspid-valve-surgery/ Wed, 29 Apr 2026 15:02:20 +0000 https://clinicaltrials.eu/trial/study-of-levosimendan-vs-placebo-for-patients-with-right-ventricular-dysfunction-undergoing-tricuspid-valve-surgery/ This study focuses on patients who need surgery for tricuspid regurgitation, a heart condition where one of the heart valves (the tricuspid valve) doesn’t close properly, causing blood to flow backward. The study examines the effectiveness of a medication called levosimendan (ZIMINO) compared to placebo in preventing complications after heart surgery.

The purpose of this research is to determine if giving levosimendan before surgery can help prevent a condition called low cardiac output syndrome, which occurs when the heart cannot pump enough blood to meet the body’s needs after surgery. During the study, patients will receive either levosimendan or placebo through an intravenous infusion before their tricuspid valve surgery.

The medication or placebo will be given as a single treatment before the surgery. After the operation, patients will be monitored for 90 days to check for signs of heart-related complications, including the need for additional medications to support heart function, the use of devices to help the heart pump blood, or the need for special treatments to support kidney function.

]]> Study on Dapagliflozin for Reducing Atrial Fibrillation and Kidney Injury in Patients Awaiting Coronary Artery Bypass Surgery https://clinicaltrials.eu/trial/study-on-dapagliflozin-for-reducing-atrial-fibrillation-and-kidney-injury-in-patients-awaiting-coronary-artery-bypass-surgery/ Wed, 29 Apr 2026 14:25:21 +0000 https://clinicaltrials.eu/trial/study-on-dapagliflozin-for-reducing-atrial-fibrillation-and-kidney-injury-in-patients-awaiting-coronary-artery-bypass-surgery/ This clinical trial is focused on patients who are waiting to undergo coronary artery bypass surgery, a procedure to improve blood flow to the heart. The study is investigating the use of a medication called dapagliflozin, which is a type of drug known as an SGLT2 inhibitor. The main goal is to see if dapagliflozin can help reduce the risk of developing new onset atrial fibrillation, a type of irregular heartbeat, and acute kidney injury after the surgery.

Participants in the study will be given either dapagliflozin or a placebo, which looks like the real medication but does not contain any active ingredients. The study will take place over a period of time, starting before the surgery and continuing through the hospital stay. Researchers will monitor the participants for any signs of atrial fibrillation or kidney injury, as well as other health outcomes such as heart failure, stroke, and overall safety of the medication.

The study aims to provide valuable information on whether dapagliflozin can be an effective treatment to improve recovery and reduce complications after coronary artery bypass surgery. Participants will be closely observed during their hospital stay and for a period after discharge to ensure their safety and to gather comprehensive data on the effects of the treatment.

]]>